76263-21-3

Basic information

• Product Name: 3-(4-Trifluoromethyl-phenoxy)-azetidine
• Synonyms: 3-(4-Trifluoromethyl-phenoxy)-azetidine;Azetidine,3-[4-(trifluoromethyl)phenoxy]-;3-[4-(Trifluoromethyl)phenoxy] azetidine hydrochloride
• CAS NO: 76263-21-3
• Molecular Formula: C₁₀H₁₀F₃NO
• Molecular Weight: 217.1877096
• Mol File: 76263-21-3.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 257℃
• Flash Point: 109℃
• Appearance: /
• Density: 1.277
• Vapor Pressure: 0.0146mmHg at 25°C
• Refractive Index: 1.481
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-(4-Trifluoromethyl-phenoxy)-azetidine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-Trifluoromethyl-phenoxy)-azetidine(76263-21-3)
• EPA Substance Registry System: 3-(4-Trifluoromethyl-phenoxy)-azetidine(76263-21-3)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 76263-21-3(Hazardous Substances Data)

Usage

General Description

3-(4-Trifluoromethyl-phenoxy)-azetidine is a chemical compound with a molecular formula C10H10F3NO that is used in research and development. It is a member of the azetidine family of compounds and features a trifluoromethyl-substituted phenoxy group attached to a four-membered azetidine ring. 3-(4-Trifluoromethyl-phenoxy)-azetidine has potential applications in pharmaceuticals, agrochemicals, and materials science due to its unique structure and potential biological activity. Further research is needed to fully understand the properties and potential uses of 3-(4-Trifluoromethyl-phenoxy)-azetidine.

InChI:InChI=1/C10H10F3NO/c11-10(12,13)7-1-3-8(4-2-7)15-9-5-14-6-9/h1-4,9,14H,5-6H2

Upstream product

• 232600-32-7 1-(diphenylmethyl)-3-[4-(trifluoromethyl)phenoxy]azetidine 
• 402-45-9 4-hydroxybenzotrifluoride 
• 141699-55-0 tert-butyl 3-hydroxyazetidine-1-carboxylate 

Downstream Products

• 106859-93-2 N-Ethyl-3-[4-(trifluoromethyl)phenoxy]-1-azetidinecarboxamide 

Relevant articles and documents

ROR [gamma]t inhibitor, preparation method and application thereof

The invention relates to the technical field of medicines, in particular to an ROR [gamma]t inhibitor, a preparation method and application thereof. The invention also relates to a pharmaceutical composition containing the compound, a method for preparing the pharmaceutical composition, and application of the compound or the pharmaceutical composition in treatment or prevention of ROR [gamma]t-mediated cancers, inflammations or autoimmune diseases of mammals, especially human beings.

NEW HETEROCYCLIC COMPOUNDS AS MONOACYLGLYCEROL LIPASE INHIBITORS

The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS

The invention relates pyridine amide derivative of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are independently hydrogen, linear o branched (C1-C3)alkyl or joined together they form a cyclopropyl ring; R is independently selected from the group consisting of halogens and trifluoromethyl and p is 1, 2 or 3; A is C or N; E is a group of formula (B) or (C), wherein B is C(O)OH, C(O)O(C1-C3)alkyl, and C is selected from the group consisting of formula (I) m is 1,2 or 3, n is 0 or 1, W is -O-, -O(C1-C3 alkyl)-; -(C1-C3 alkyl)O-; -C(O)-; -C(=N-O(C1-C3 alkyl))-; -NH- or -NH(C1-C3alkyl)-; Ar is phenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, trifluoromethyl, trifluoromethoxy, methyl, -NH(C1-C3alkyl)-; -N(C1-C3alkyl)(C1-C3alkyl)-, a from 5 to 7 membered heterocyclic ring containing one nitrogen atom which is convalently bonded to Ar and optionally containing one or two heteroatoms selected from N, O and S; and a 5- or 6-membered heteroaromatic ring containing 1 to 3 heteroatoms selected from S, O e N, such heteroaromatic ring being substituted with one or two substituents selected from the group consisting of (C1-C3)alkyl, (C3-C5)cycloalkyloxy, (C1-C3)alkylcarbonyl. The compounds of the invention could be used for manufacturing a medicament for the treatment of pathologies which require the use of an antagonist of the EP4 receptor, such as the treatment of acute and chronic pain, inflammatory pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid artrhritis, cancer, endometriosis and migraine.